Protein / target
Guanylate cyclase soluble subunit beta-2
Protein at a glance
Biological role
Guanylate cyclase
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Subcellular location
Domains and Gene Ontology detail (10)Hide
Domains & features
Gene Ontology
- Ccytosol
- Cguanylate cyclase complex, soluble
- FGTP binding
- Fguanylate cyclase activity
- Fheme binding
- Fmetal ion binding
- Pintracellular signal transduction
- Presponse to oxygen levels
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Soluble guanylate cyclase activator
Indicated for Hypertension, Pulmonary, Respiratory Insufficiency, Respiratory Tract Diseases
Soluble guanylate cyclase positive allosteric modulator
Indicated for Familial Primary Pulmonary Hypertension, Hypertension, Hypertension, Pulmonary
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
A Multicentre Randomised Cross-over Trial of Disease Specific Therapy in Patients With Pulmonary Arterial Hypertension (PAH) Implanted With Pulmonary Artery Pressure and Cardiac Rhythm Monitoring Devices (CardioMEMS/ConfirmRx)
- Supplemental approval
Supplemental approval: RIOCIGUAT (ANDA211135)
- Supplemental approval
Supplemental approval: RIOCIGUAT (NDA204819)
- CHMP positive opinion
CHMP positive opinion: Riociguat Accord (EMA)
- Supplemental approval
Supplemental approval: RIOCIGUAT (ANDA211135)
- Supplemental approval
Supplemental approval: RIOCIGUAT (NDA204819)
- New publicationUnderstanding chronic inflammation: couplings between cytokines, ROS, NO, Ca<sub>i</sub> <sup>2+</sup>, HIF-1α, Nrf2 and autophagy.
- New publicationNeurological Manifestations Following Traumatic Brain Injury: Role of Behavioral, Neuroinflammation, Excitotoxicity, Nrf-2 and Nitric Oxide.
- New publicationSystemic and Cardiac Microvascular Dysfunction in Hypertension.
- New publicationThe Unexpected Role of the Endothelial Nitric Oxide Synthase at the Neurovascular Unit: Beyond the Regulation of Cerebral Blood Flow.
- New publicationCa<sup>2+</sup>-dependent phosphodiesterase 1 regulates the plasticity of striatal spiny projection neuron glutamatergic synapses.
- Safety communication
Drug Safety Update: Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.